Oncolytics Biotech (U.K.) Ltd 07645726 development stage biopharmaceutical company true 1 January 2024 07645726 2024-01-01 2024-12-31 07645726 2023-12-31 07645726 2024-12-31 07645726 2023-01-01 2023-12-31 07645726 2022-12-31 07645726 2023-12-31 07645726 frs102-bus:FRS102 2024-01-01 2024-12-31 07645726 frs102-bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 07645726 frs102-bus:FullAccounts 2024-01-01 2024-12-31 07645726 frs102-bus:AuditExempt-NoAccountantsReport 2024-01-01 2024-12-31 07645726 frs102-bus:EntityNoLongerTradingButTradedInPast 2024-01-01 2024-12-31 07645726 frs102-core:CurrentFinancialInstruments 2024-12-31 07645726 frs102-core:CurrentFinancialInstruments 2023-12-31 07645726 frs102-core:ShareCapital 2024-12-31 07645726 frs102-core:ShareCapital 2023-12-31 07645726 frs102-core:OtherReservesSubtotal 2024-12-31 07645726 frs102-core:OtherReservesSubtotal 2023-12-31 07645726 frs102-core:RetainedEarningsAccumulatedLosses 2024-12-31 07645726 frs102-core:RetainedEarningsAccumulatedLosses 2023-12-31 07645726 frs102-bus:Director1 2024-01-01 2024-12-31 07645726 frs102-bus:OrdinaryShareClass1 2024-12-31 07645726 frs102-bus:OrdinaryShareClass1 2023-12-31 07645726 frs102-bus:OrdinaryShareClass1 2024-01-01 2024-12-31 xbrli:pure iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares
Registered number
07645726
Oncolytics Biotech (U.K.) Ltd
Amended Unaudited Accounts
for the year ended
31 December 2024
Oncolytics Biotech (U.K.) Ltd
Balance Sheet
as at 31 December 2024
Notes
2024
£
2023
£
Creditors: amounts falling due within one year (243,364) (243,364)
Net current assets / (liabilities) (243,364) (243,364)
Total assets less current liabilities (243,364) (243,364)
Provisions for liabilities (0) (0)
Total net assets (liabilities) (243,364) (243,364)
Capital and reserves
Called up share capital 2 100 100
Other reserves 14,908 14,908
Profit and loss account (258,372) (258,372)
Shareholders' funds (243,364) (243,364)

Oncolytics Biotech (U.K.) Ltd
Balance Sheet
as at 31 December 2024



These accounts have been prepared and delivered in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

The directors have not delivered a copy of the company's Profit and Loss account as permitted by s444(5A) of the Companies Act 2006.

For the year ending 31 December 2024 the company was entitled to exemption as a dormant company under section 480 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

Signed on behalf of the board of directors

...............................

Mr. K Look

Director


Approved by the board on 30 January 2025

Company Number: 07645726 (a Private Company Limited by Shares registered in England and Wales)

Registered Office:

C/o Mccarthy Tetrault 1 Angel Court
18th Floor
London
EC2R 7HJ
England

Oncolytics Biotech (U.K.) Ltd
Notes to the Accounts
for the year ended 31 December 2024

1. Accounting policies

Basis of preparation of financial statements
These financial statements have been prepared under the historic cost convention in accordance with the accounting policies set out below and with section 1A of FRS 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland, and the Companies Act 2006. The presentation currency is sterling.
2. Share capital
2024 2023
£ £
Allotted, called up and fully paid:
1 (2023: 1) Ordinary shares of £100.00 each 100 100
100 100

3. Related party disclosures

During the period of accounts a transaction occurred between this company and a related party, Oncolytics Biotech Inc.. The relationship between the parties is Ultimate Parent. At the balance sheet date the related party owed the company £226,472 (2023 - £226,272).

During the period of accounts a transaction occurred between this company and a related party, Oncolytics Biotech (Barbados) Inc Inc. The relationship between the parties is Parent. At the balance sheet date the related party owed the company £16,892 (2023 - £16,892).


Controlling party
Controlling party
Amounts due to and from related parties are interest free, unsecured and payable on demand. The transactions were entered in the ordinary course of business.

a.) Parent entities
The Company is a 100% subsidiary undertaking of Oncolytics Biotech (Barbados) Inc., which is a 100% subsidiary of Oncolytics Biotech Inc.





4. Other information

Share based payment reserve
In previous years employees were granted stock options that are settled in equity from the
company's ultimate parent company, Oncolytics Biotech Inc. for the services provided to Oncolytics
Biotech (UK) Inc. The Company has recorded these amounts as share based compensation expense and
recorded the corresponding credit in share based payment reserve.

There were no shared based payment expenses in the current and preceding year. As well, there were
no options outstanding at the end of 2024 and 2023.